Claims for Patent: 10,253,095

Summary for Patent: 10,253,095

Title:	Anti-KIR combination treatments and methods
Abstract:	Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.
Inventor(s):	Romagne; Francois (Marseille, FR), Wagtmann; Peter Andreas Nicolai Reumert (Rungsted Kyst, DK), Glamann; Joakim (Gentofte, DK)
Assignee:	INNATE PHARMA S.A.S. (Marseilles, FR) NOVO NORDISK A/S (Bagsvaerd, DK)
Application Number:	13/183,602
Patent Claims:	1. A method of treating melanoma in a human subject, comprising administering to the subject (a) a KIR2DL1 and KIR2DL2/3 cross-reactive anti-KIR antibody or antibody fragment that binds to KIR2DL1 or KIR2DL2/3 on a natural killer(NK) cell and blocks KIR2DL1- and KIR2DL2/3-mediated inhibition of NK cell cytotoxicity, thereby potentiating NK cell cytotoxicity, wherein the V.sub.H chain of the antibody or antibody fragment comprises the V.sub.H CDRs of a V.sub.H chain having the amino acid sequence set forth in SEQ ID NO: 13 and the V.sub.L chain of the antibody or antibody fragment comprises the V.sub.L CDRs of a V.sub.L chain having the amino acid sequence set forth in SEQ ID NO: 15, and (b) human interleukin-2 (IL-2), thereby treating the melanoma, wherein the administration of said anti-KIR antibody or antibody fragment and said IL-2 elicits an NK cell-mediated anti-tumor immune response, and further wherein the administered dosage of said anti-KIR antibody or antibody fragment in the absence of said human IL-2 does not elicit a detectable effect on tumor size, wherein the administered dosage of said human IL-2 in the absence of said anti-KIR antibody or antibody fragment does not elicit a statistically significant effect on tumor size, and wherein said administered dosage of said anti-KIR antibody or antibody fragment and said human IL-2 results in a statistically significant reduction of tumor size. 2. The method of claim 1, wherein the method does not include administration of rituximab and/or alemtuzumab to the subject. 3. The method of claim 1, wherein the KIR2DL1 and KIR2DL2/3 cross-reactive anti-KIR antibody or antibody fragment and the IL-2 are the sole pharmaceutically active agents administered to the subject for the treatment. 4. The method of claim 1, wherein the administration of said anti-KIR antibody or antibody fragment and said IL-2 elicits a synergistic effect on NK cell-mediated anti-tumor immunity. 5. The method of claim 1, wherein the melanoma cells are cutaneous melanoma cells, ocular melanoma cells, and/or lymph node-associated melanoma cells. 6. The method of claim 1, wherein the melanoma is metastatic. 7. The method of claim 1, wherein the antibody or antibody fragment comprises a V.sub.H chain having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 13 and a V.sub.L chain having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 15.

Details for Patent 10,253,095

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2025-01-06
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2025-01-06
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2025-01-06
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004		2025-01-06
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2025-01-06